Literature DB >> 35601718

Standard- versus High-Dose Dexmedetomidine for Sedation in the Intensive Care Unit.

Megan Van Berkel Patel1, Spencer Bolton2, Cassie Hamilton1.   

Abstract

Background: Dexmedetomidine is a commonly used sedative in the intensive care unit (ICU), however the use of higher, off label dosing has yet to be elucidated. A dose limitation protocol was implemented at our institution allowing for comparison of dexmedetomidine doses. Objective: The purpose of this study is to evaluate time spent within goal Richmond Agitation Sedation Scale (RASS) range with standard-dosing of dexmedetomidine ≤1 mcg/kg/hour (SD group) compared to high-dose >1 mcg/kg/hour (HD group). Secondary outcomes included days requiring mechanical ventilation, concomitant sedation, and incidence of hypotension or bradycardia.
Methods: This retrospective chart review of adult ICU patients at a single academic medical center included patients who required at least 24 hours of mechanical ventilation and received dexmedetomidine monotherapy for at least 4 hours. Patients were excluded for intubations at an outside hospital, continuous neuromuscular blocking infusions, or Glasgow Coma Score ≤4.
Results: A total of 144 patients met inclusion criteria (n = 121 SD group and n = 23 HD group). The SD group spent a greater time within goal RASS range compared to the HD group (84.5% [IQR 47-100] vs 45.5% [IQR 30.1-85.4], P = .013). The SD group also had shorter durations of both dexmedetomidine infusion and mechanical ventilation, and required less concomitant sedation. There was no difference in hypotension or bradycardia.
Conclusion: This study further adds to the literature that administration of high-dose dexmedetomidine does not appear to confer additional benefit over standard doses for ICU patients requiring mechanical ventilation. Application of this data may support lower institutional maximum doses.
© The Author(s) 2021.

Entities:  

Keywords:  cost effectiveness; critical care; dexmedetomidine; intravenous therapy; sedation

Year:  2021        PMID: 35601718      PMCID: PMC9117786          DOI: 10.1177/00185787211029552

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  6 in total

Review 1.  Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

2.  Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials.

Authors:  Stephan M Jakob; Esko Ruokonen; R Michael Grounds; Toni Sarapohja; Chris Garratt; Stuart J Pocock; J Raymond Bratty; Jukka Takala
Journal:  JAMA       Date:  2012-03-21       Impact factor: 56.272

3.  High-dose dexmedetomidine for sedation in the intensive care unit: an evaluation of clinical efficacy and safety.

Authors:  G Morgan Jones; Claire V Murphy; Anthony T Gerlach; Erin M Goodman; Lindsay J Pell
Journal:  Ann Pharmacother       Date:  2011-06-10       Impact factor: 3.154

4.  Evaluation of dexmedetomidine: safety and clinical outcomes in critically ill trauma patients.

Authors:  Sandeep Devabhakthuni; Mehrnaz Pajoumand; Carla Williams; Joseph A Kufera; Kristin Watson; Deborah M Stein
Journal:  J Trauma       Date:  2011-11

5.  A new dosing protocol reduces dexmedetomidine-associated hypotension in critically ill surgical patients.

Authors:  Anthony T Gerlach; Joseph F Dasta; Steven Steinberg; Larry C Martin; Charles H Cook
Journal:  J Crit Care       Date:  2009-08-13       Impact factor: 3.425

6.  Age related inverse dose relation of sedatives and analgesics in the intensive care unit.

Authors:  Amartya Mukhopadhyay; Bee Choo Tai; Deepa Remani; Jason Phua; Matthew Edward Cove; Yanika Kowitlawakul
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.